The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Vertigon     2-chloro-10-[3-(4- methylpiperazin-1...

Synonyms: Capazine, Emetiral, Eskatrol, Kronocin, Stemetil, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Vertigon


Psychiatry related information on Vertigon


High impact information on Vertigon


Chemical compound and disease context of Vertigon


Biological context of Vertigon


Anatomical context of Vertigon

  • The temperature-dependent instability of glucose-6-P'ase was increased by treatment of microsomes with prochlorperazine and could be prevented only partially by substrate [24].
  • We conclude that prochlorperazine disrupts the structural organization between lipids and proteins in microsomal membranes, altering thereby the activity and regulation of at least two different integral membrane proteins [24].
  • We have studied the effects of prochlorperazine on the activities of UDP-glucuronosyltransferase and glucose-6-phosphatase (glucose-6-P'ase) in rat liver microsomes [24].
  • The IC50 for a prochlorperazine block of HERG current in Xenopus oocytes progressively decreased relative to the degree of depolarization, from 42.1 microM at -40 mV to 37.4 microM at 0 mV to 22.6 microM at +40 mV [25].
  • In guinea pig ventricular myocytes, bath applications of 0.5 and 1 muM prochlorperazine at 36 degrees C blocked rapidly activating delayed rectifier K+ current by 38.9% and 76.5%, respectively, but did not significantly block slowly activating delayed rectifier K+ current [25].

Associations of Vertigon with other chemical compounds


Gene context of Vertigon


Analytical, diagnostic and therapeutic context of Vertigon


  1. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. Gralla, R.J., Itri, L.M., Pisko, S.E., Squillante, A.E., Kelsen, D.P., Braun, D.W., Bordin, L.A., Braun, T.J., Young, C.W. N. Engl. J. Med. (1981) [Pubmed]
  2. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. Jones, J., Sklar, D., Dougherty, J., White, W. JAMA (1989) [Pubmed]
  3. Severe parkinsonism in two AIDS patients taking prochlorperazine. Edelstein, H., Knight, R.T. Lancet (1987) [Pubmed]
  4. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. Silvey, L., Carpenter, J.T., Wheeler, R.H., Lee, J., Conolley, C. J. Clin. Oncol. (1988) [Pubmed]
  5. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Chen, J.J., Frame, D.G., White, T.J. Arch. Intern. Med. (1998) [Pubmed]
  6. Akathisia from prochlorperazine. Weiden, P. JAMA (1985) [Pubmed]
  7. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Zhang, H., Zhang, J., Streisand, J.B. Clinical pharmacokinetics. (2002) [Pubmed]
  8. Infantile auditory exposure and unusual response to antipsychiotic drugs (38510). Iturrian, W.B., Johnson, H.D. Proc. Soc. Exp. Biol. Med. (1975) [Pubmed]
  9. Abortive migraine therapy in the office with dexamethasone and prochlorperazine. Saadah, H.A. Headache. (1994) [Pubmed]
  10. Extrapyramidal side effects of antiemetics presenting as psychiatric illness. Rodgers, C. General hospital psychiatry. (1992) [Pubmed]
  11. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. Fraschini, G., Ciociola, A., Esparza, L., Templeton, D., Holmes, F.A., Walters, R.S., Hortobagyi, G.N. J. Clin. Oncol. (1991) [Pubmed]
  12. Antiemetic-induced akathisia in cancer patients receiving chemotherapy. Fleishman, S.B., Lavin, M.R., Sattler, M., Szarka, H. The American journal of psychiatry. (1994) [Pubmed]
  13. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Kaatz, G.W., Moudgal, V.V., Seo, S.M., Kristiansen, J.E. Antimicrob. Agents Chemother. (2003) [Pubmed]
  14. In vitro activities of chloroquine in combination with chlorpromazine or prochlorperazine against isolates of Plasmodium falciparum. Basco, L.K., Le Bras, J. Antimicrob. Agents Chemother. (1992) [Pubmed]
  15. A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study. Carr, B.I., Bertrand, M., Browning, S., Doroshow, J.H., Presant, C., Pulone, B., Hill, L.R. J. Clin. Oncol. (1985) [Pubmed]
  16. Effects of extracellular calmodulin and calmodulin antagonists on B16 melanoma cell growth. Mac Neil, S., Walker, S.W., Senior, H.J., Bleehen, S.S., Tomlinson, S. J. Invest. Dermatol. (1984) [Pubmed]
  17. Sensitization of Burkholderia cepacia to antibiotics by cationic drugs. Rajyaguru, J.M., Muszynski, M.J. J. Antimicrob. Chemother. (1998) [Pubmed]
  18. A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy. Bishop, J.F., Matthews, J.P., Wolf, M.M., Oliver, I.N., Reynolds, S., Walpole, E., Rischin, D., Buchanan, L., Tan, L.G. Eur. J. Cancer (1992) [Pubmed]
  19. Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy. Dziuk, T., Senzer, N. Semin. Oncol. (2003) [Pubmed]
  20. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. Sridhar, K.S., Krishan, A., Samy, T.S., Duncan, R.C., Sauerteig, A., McPhee, G.V., Auguste, M.E., Benedetto, P.W. Cancer Chemother. Pharmacol. (1994) [Pubmed]
  21. Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazine administered as a thermally generated aerosol in a single breath to dogs. Avram, M.J., Henthorn, T.K., Spyker, D.A., Krejcie, T.C., Lloyd, P.M., Cassella, J.V., Rabinowitz, J.D. Drug Metab. Dispos. (2007) [Pubmed]
  22. Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. Morgan, R.J., Synold, T., Carr, B.I., Doroshow, J.H., Womack, E.P., Shibata, S., Somlo, G., Raschko, J., Leong, L., McNamara, M., Chow, W., Tetef, M., Margolin, K., Akman, S., Longmate, J. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  23. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Cagnoni, P.J., Matthes, S., Day, T.C., Bearman, S.I., Shpall, E.J., Jones, R.B. Bone Marrow Transplant. (1999) [Pubmed]
  24. Effects of prochlorperazine on the function of integral membrane proteins. Dannenberg, A., Zakim, D. Biochem. Pharmacol. (1988) [Pubmed]
  25. Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine. Kim, M.D., Eun, S.Y., Jo, S.H. Eur. J. Pharmacol. (2006) [Pubmed]
  26. Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. Bishop, J.F., Olver, I.N., Wolf, M.M., Matthews, J.P., Long, M., Bingham, J., Hillcoat, B.L., Cooper, I.A. J. Clin. Oncol. (1984) [Pubmed]
  27. Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy. Goldstein, D., Levi, J.A., Woods, R.L., Russell, J., Morgan, J., Kerestes, Z. Oncology (1989) [Pubmed]
  28. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Jeding, I., Evans, P.J., Akanmu, D., Dexter, D., Spencer, J.D., Aruoma, O.I., Jenner, P., Halliwell, B. Biochem. Pharmacol. (1995) [Pubmed]
  29. Radioligand binding and photoaffinity labelling studies show a direct interaction of phenothiazines at 5-HT3 receptors. Lummis, S.C., Baker, J. Neuropharmacology (1997) [Pubmed]
  30. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Tramèr, M.R., Reynolds, D.J., Stoner, N.S., Moore, R.A., McQuay, H.J. Eur. J. Cancer (1998) [Pubmed]
  31. Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil). Devlin, J., Wagstaff, K., Arthur, V., Emery, P. Rheumatology (Oxford, England) (1999) [Pubmed]
  32. Effects of somatostatin, naloxone and prochlorperazine on the control of ventilation in man. Maxwell, D.L., Nolop, K.B., Hughes, J.M. Clin. Sci. (1986) [Pubmed]
  33. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. Herman, T.S., Einhorn, L.H., Jones, S.E., Nagy, C., Chester, A.B., Dean, J.C., Furnas, B., Williams, S.D., Leigh, S.A., Dorr, R.T., Moon, T.E. N. Engl. J. Med. (1979) [Pubmed]
  34. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Frytak, S., Moertel, C.G., O'Fallon, J.R., Rubin, J., Creagan, E.T., O'Connell, M.J., Schutt, A.J., Schwartau, N.W. Ann. Intern. Med. (1979) [Pubmed]
  35. Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Ungerleider, J.T., Andrysiak, T.A., Fairbanks, L.A., Tesler, A.S., Parker, R.G. Radiology. (1984) [Pubmed]
WikiGenes - Universities